Frontage Laboratories, Inc.
Doing business as Frontage Laboratories
- UEI
- CSMHKH3DKHH8
- CAGE
- 4YMC3
- Primary NAICS
- 541711 Research and Development in Biotechnology
- SAM.gov registration
- Deleted
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- Corporate family
-
-
Frontage Laboratories, Inc.
CSMHKH3DKHH8
- Frontage Laboratories Inc. KNR8T18S3798
- Frontage Laboratories, Inc. EJEPBJH9GWF8
-
Frontage Laboratories, Inc.
CSMHKH3DKHH8
- SAM.gov registration date
- Website
- frontagelab.com
- Founded
- 2001
- Employees
- 251-1K
- Estimated annual revenue
- $100M-$250M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- SIC code
- 87 Engineering & Management Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Novel electrocardiographic biomarkers to distiguish benign from malignant drug-induced QT prolongation combined… | Food and Drug Administration | $137,670 | |
| Pharmacokinetic sample analysis of four different drugs from a prospective clinical study | Food and Drug Administration | $69,813 | |
| The purpose of modification 0001 is to complete the administrative action and financial DE-obligation for the FY13… | National Institute on Drug Abuse | $18,628 | |
| Frontage laboratories, INC. [10-002204] | National Institute on Drug Abuse | $10,579 | |
| Pots# 09-030459, PAT andrews, bldg 10/4N208, method development validation | National Institute on Drug Abuse | $36,200 |
About Frontage Laboratories, Inc.
Frontage Laboratories, Inc., doing business as Frontage Laboratories, is a minority-owned, Asian-Pacific American owned business that has been registered to receive federal contract awards since January 2008. The company is structured as a corporate entity and is classified as a manufacturer of goods, indicating its involvement in the production of tangible products. Frontage Laboratories primarily provides scientific research and laboratory services to various agencies within the U.S. Department of Health and Human Services, particularly the National Institutes of Health (NIH). Their work predominantly focuses on pharmacokinetics, drug metabolism, and the synthesis of specialized compounds for medical research purposes.
The contract awards received by Frontage Laboratories demonstrate their expertise in a range of specialized scientific services. These include pharmacokinetic analysis of small molecules, synthesis of thyclotides and Fmoc-thyclotide monomers, metabolite identification in various species' hepatocytes, and blood stability and metabolism studies of specific compounds. The company has worked on projects related to diabetes, digestive, and kidney diseases for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), as well as contributing to COVID-19 research for the National Center for Advancing Translational Sciences. Notably, none of the recent contract awards utilized set-aside designations, suggesting that Frontage Laboratories competes successfully in open bidding processes. The contract types are typically purchase orders with values ranging from $22,500 to $126,850, indicating discrete, specialized research tasks rather than long-term service agreements.
Quick answers
What is Frontage Laboratories, Inc.'s UEI?
Frontage Laboratories, Inc.'s Unique Entity ID (UEI) in SAM.gov is CSMHKH3DKHH8.
What is Frontage Laboratories, Inc.'s CAGE code?
Frontage Laboratories, Inc.'s CAGE code is 4YMC3.
What is Frontage Laboratories, Inc.'s primary NAICS code?
Frontage Laboratories, Inc.'s primary NAICS code is 541711 (Research and Development in Biotechnology).
Is Frontage Laboratories, Inc. registered in SAM.gov?
Frontage Laboratories, Inc.'s SAM.gov registration was deleted on September 25, 2015.
What is Frontage Laboratories, Inc.'s most recent federal award?
Frontage Laboratories, Inc.'s most recent federal contract award is Novel electrocardiographic biomarkers to distiguish benign from malignant drug-induced QT prolongation combined… (HHSF223201400209A), from Food and Drug Administration, on July 15, 2014.
On GovTribe
See Frontage Laboratories, Inc.'s full federal record
- Federal contract awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors